SHIELD THERAPEUTICS PLC — Investor Relations & Filings
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Grant of Share Options | 2026-05-05 | English | |
| Q1 2026 Trading Update | 2026-05-01 | English | |
| Total Voting Rights | 2026-04-30 | English | |
| Enrollment in Phase II Clinical Trial for ACCRUFeR | 2026-04-27 | English | |
| Audited results for year ended 31 December 2025 | 2026-04-09 | English | |
| Publication of Report, Reinforcing FDA Approval | 2026-04-01 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41263201 | Grant of Share Options | 2026-05-05 | English | ||
| 39399233 | Q1 2026 Trading Update | 2026-05-01 | English | ||
| 39019036 | Total Voting Rights | 2026-04-30 | English | ||
| 37325589 | Enrollment in Phase II Clinical Trial for ACCRUFeR | 2026-04-27 | English | ||
| 33979107 | Audited results for year ended 31 December 2025 | 2026-04-09 | English | ||
| 33556496 | Publication of Report, Reinforcing FDA Approval | 2026-04-01 | English | ||
| 33102131 | Total Voting Rights | 2026-03-31 | English | ||
| 33101967 | EMA approves extension - to include adolescents | 2026-03-31 | English | ||
| 32869324 | Chinese NMPA Accepts MAA Submission for ACCRUFeR® | 2026-03-03 | English | ||
| 32843910 | Total Voting Rights | 2026-02-27 | English | ||
| 18023058 | FDA Grants additional Exclusivity for ACCRUFeR | 2026-02-09 | English | ||
| 13759127 | Total Voting Rights | 2026-01-30 | English | ||
| 13754859 | Approval for ACCRUFeR in China expected in Q1 2026 | 2026-01-30 | English | ||
| 13132786 | Q4 2025 Trading Update | 2026-01-21 | English | ||
| 11753277 | Block listing 6 Monthly Return | 2026-01-02 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for SHIELD THERAPEUTICS PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
SHIELD THERAPEUTICS PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7914/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7914 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7914 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7914 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7914}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SHIELD THERAPEUTICS PLC (id: 7914)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.